Rocky Mountain MS Research Group

Rocky Mountain MS Research Group is a specialized clinical research center based in Salt Lake City, Utah, dedicated to advancing treatments for Multiple Sclerosis (MS) and other neuroimmunological conditions. Led by Medical Director Dr. John Foley, the organization operates as a high-volume clinical trial site that partners with global pharmaceutical companies to conduct Phase 1 through Phase 4 studies. The center is particularly recognized for its expertise in evaluating novel disease-modifying therapies, including B-cell depleting agents, S1P receptor modulators, and Bruton's tyrosine kinase (BTK) inhibitors. By integrating cutting-edge research with comprehensive patient care, the group provides participants with access to investigational treatments while contributing vital data to the global MS research community. Their facility is equipped to manage complex infusion protocols and long-term observational studies, making them a key player in the development of next-generation neurological therapies.